Mountain View, CA and Tokyo, Japan -- February 1, 2007 -- REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today the relocation of its US offices from San Jose to Mountain View, California.

"The move to this new facility allows us to establish our own labs with all members of our development team located here. We expect our drug development program will be accelerated with this consolidation," commented Haru Morita, President and Chief Executive Officer.

About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company's proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan. The US subsidiary is located at 320 Logue Ave., , Mountain View, CA 94043. Telephone: 650.938.6530.